Research programme: BACE1 protein inhibitors - Allergan/Boehringer Ingelheim

Drug Profile

Research programme: BACE1 protein inhibitors - Allergan/Boehringer Ingelheim

Alternative Names: BACE1 inhibitors - Allergan; Beta secretase inhibitors - Allergan; BI 1147560; VTP 36951

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Allergan; Boehringer Ingelheim
  • Class Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
  • 27 Jul 2015 Vitae Pharmaceuticals and Boehringer Ingelheim to end collaboration and license agreement for BACE inhibitors
  • 01 Apr 2015 Boehringer Ingelheim plans a phase I trial for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top